Information Provided By:
Fly News Breaks for May 9, 2017
LH, PRXL
May 9, 2017 | 06:27 EDT
Jefferies analyst David Windley believes a sale of Parexel (PRXL), which the Wall Street Journal reported yesterday is under consideration, is "likely the best way to fix the company for many reasons." Parexel has been suggested as one of LabCorp's (LH) interests, but LabCorp management may not want to take on such a deal, Windley tells investors in a research note. Parexel changes are more easily undertaken in private, he contends. The analyst has a Hold rating on the shares with a $66 price target.
News For PRXL;LH From the Last 2 Days
There are no results for your query PRXL;LH